azacitidine has been researched along with Abnormal Karyotype in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuoka, A; Tanibuchi, M; Taoka, T; Yamazaki, I | 1 |
| Chinen, S; Fuchida, SI; Fujino, T; Hirakawa, K; Inoue, Y; Kaneko, H; Kawaji-Kanayama, Y; Kawata, E; Kuroda, J; Kuwahara-Ota, S; Miyashita, A; Mizutani, S; Nishiyama, D; Okamoto, H; Shimura, Y; Tsukamoto, T; Uchiyama, H; Uoshima, N | 1 |
| Adès, L; Angeli, E; Bally, C; Calleja, A; Chevallier, P; Cluzeau, T; Fenaux, P; Garnier, A; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Ngo Nloga, AM; Peterlin, P | 1 |
| Chang, C; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Q; Zhang, X; Zhang, Z; Zhou, L | 1 |
| Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Dervenoulas, I; Dimitriadis, G; Economopoulos, T; Girkas, K; Karvounis, K; Pagageorgiou, S; Pappa, V; Sambani, C; Stathopoulou, E; Tsirigiotis, P | 1 |
| Cornfield, DB | 1 |
7 other study(ies) available for azacitidine and Abnormal Karyotype
| Article | Year |
|---|---|
Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine.
Topics: Abnormal Karyotype; Aged; Antimetabolites, Antineoplastic; Azacitidine; Erythroblasts; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2022 |
Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.
Topics: Abnormal Karyotype; Azacitidine; Humans; Myelodysplastic Syndromes; Prognosis; Retrospective Studies | 2023 |
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
Topics: Abnormal Karyotype; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Diseases; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Febrile Neutropenia; Female; France; Hospitalization; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2020 |
Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Topics: Abnormal Karyotype; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytogenetic Analysis; Decitabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Risk Assessment; Survival Rate | 2013 |
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Topics: Abnormal Karyotype; Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Azacitidine in a patient with newly diagnosed acute myeloid leukemia and poor risk cytogenetics: outcomes of prolonged therapy.
Topics: Abnormal Karyotype; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Risk; Treatment Outcome | 2012 |
Erythroblastic sarcoma, an extremely rare variant of myeloid sarcoma.
Topics: Abnormal Karyotype; Adenocarcinoma; Aged; Azacitidine; Biopsy, Large-Core Needle; Bone Marrow; Bone Marrow Neoplasms; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Erythroblasts; Erythropoietin; Fatal Outcome; Humans; Lymph Nodes; Male; Myelodysplastic Syndromes; Rare Diseases; Rectal Neoplasms; Sarcoma, Myeloid | 2012 |